Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries
Data from latest research presented at the ESMO Virtual Congress 2020
The full scientific programme of the ESMO Congress 2020 (19-21 September) is now available online.
The European Society for Medical Oncology has announced the winners of the ESMO awards 2020.
Recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers are being launched today by ESMO
The science weekend of the ESMO Congress 2020 will be held as a virtual meeting between 19 and 21 September.
In Annals of Oncology, ESMO’s comprehensive set of recommendations address open questions on how to manage cancer care in the COVID-19 era
The ESMO Congress 2020 will be held as a virtual meeting, with the programme delivered over two weekends:
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.